Could Moderna and AstraZeneca's mRNA Heart Failure Drug Candidate Be a Winner?

Moderna (NASDAQ: MRNA) and AstraZeneca (NASDAQ: AZN) compete against each other in some markets with their respective COVID-19 vaccines. However, the two companies are also partners. They recently reported results from a phase 2 study of a messenger RNA (mRNA) heart failure drug. In this Motley Fool Live video recorded on Nov. 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Moderna's and AstraZeneca's mRNA candidate could be a winner.

Continue reading

Source Fool.com